Lifeward Ltd. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Lifeward Ltd. (LFWD) on January 12, 2026. The filing discloses the entry into a Material Definitive Agreement involving the acquisition of Oratech Pharma, Inc., a wholly owned subsidiary of Oramed Pharmaceuticals, Inc., and a concurrent private placement of debt securities.
Key Financial Metrics and Transaction Terms
The filing details a complex capital restructuring and acquisition rather than standard periodic financial results. Key financial terms include:
- Acquisition Consideration: Lifeward will issue Ordinary Shares and Pre-Funded Warrants to Oramed representing approximately 49.99% of the Company's fully diluted equity capitalization upon closing (capped at 45% of outstanding shares).
- Debt Financing: The Company agreed to issue $10,000,000 in Initial Senior Secured Convertible Notes and up to $10,000,000 in Second Notes (totaling $20,000,000 potential principal).
- Debt Terms: Notes carry an 8.0% annual interest rate (increasing to 15.0% upon default), mature in 3 years, and are convertible at $0.45 per share.
- Revenue Sharing: Lifeward will pay Oramed 4% of Net Revenue from ReWalk Personal Exoskeleton products for up to 10 years or until a maximum cap is reached or market capitalization exceeds $200 million.
- Warrants: Transaction Warrants will be issued based on the Company's net cash at closing divided by a $0.45 exercise price. Common Warrants accompany the Notes, exercisable at $0.45 per share.
Material Changes and Conditions
The transaction represents a material change in the Company's capital structure and ownership. Key conditions and changes include:
- Ownership Structure: Upon closing, Oramed will hold a significant equity stake (up to 49.99%), subject to beneficial ownership limitations.
- Board Composition: The Board of Directors will expand to six members: two designated by Lifeward, two by Oramed, and two external directors.
- Second Note Funding Conditions: The $10,000,000 Second Notes are contingent on either a 150% increase in ReWalk Unit Sales (year-over-year) or the stock price exceeding $1.15 per share for 10 consecutive trading days.
- Lock-Up: Shares issued to Oramed and securities held by officers/directors are subject to a 120-day lock-up period post-closing.
Outlook, Risks, and Contingencies
Management commentary is limited to the terms of the agreements. Significant risks and contingencies identified include:
- Closing Conditions: The transaction is subject to shareholder approval, regulatory filings, and the listing of new shares on Nasdaq.
- Dilution Risk: Significant dilution is expected due to the issuance of shares, pre-funded warrants, and convertible notes.
- Performance Risk: The funding of the Second Notes is contingent on specific sales growth or stock price performance targets.
- Indemnification: Approximately 5% of the Pre-Funded Warrants are held back as recourse for Oramed's indemnification obligations for 12 months.
Investor Verification Checklist
- Verify the status of shareholder approval required for the Share Purchase Agreement and Securities Purchase Agreement.
- Confirm the Company's current net cash position to calculate the number of Transaction Warrants to be issued.
- Review the definition of "Net Revenue" in the Share Purchase Agreement to understand the scope of the 4% revenue sharing obligation.
- Monitor the stock price and ReWalk Unit Sales metrics to assess the likelihood of the Second Notes funding condition being met.
- Check for the filing of the Form S-1 registration statement required within 75 days of closing.